Vitamin D3 + K2 Supplement

## What it is This is a combination supplement pairing cholecalciferol (vitamin D3, the form synthesized in skin from UVB exposure) with menaquinone-7 (vitamin K2 MK-7, the long-chain menaquinone found in natto and fermented dairy). The two vitamins have distinct biochemical roles that converge on calcium homeostasis: D3 increases intestinal calcium absorption and renal reabsorption, raising blood calcium and providing the substrate for bone mineralization; K2 activates matrix Gla protein (MGP) and osteocalcin, the proteins that direct calcium into bone and inhibit deposition in vascular tissue. The pairing rationale is mechanistic. Vitamin D supplementation alone increases calcium absorption but does not influence where the absorbed calcium is deposited. In K2-deficient individuals, the additional calcium can theoretically increase vascular calcification, which is the basis for the popular concern that high-dose vitamin D may worsen cardiovascular outcomes. K2 co-administration is proposed to redirect calcium toward bone and away from arteries. The mechanistic argument is solid; the human trial evidence for the synergy is mostly preclinical and population-based rather than from dedicated combination RCTs. Legally both vitamins are dietary supplements globally. The US RDA for vitamin D is 600 to 800 IU/day for adults, set primarily for bone health in healthy populations. The EFSA tolerable upper intake is 4,000 IU/day. The K2 RDA is not formally established; typical recommendations are 90 to 180 mcg/day for MK-7. WADA does not list either vitamin. Vitamin D3 is one of the most-supplemented compounds globally, with widespread population deficiency in temperate latitudes and in adults with limited sun exposure. The Endocrine Society defines deficiency as serum 25(OH)D below 20 ng/mL (50 nmol/L) and insufficiency as 20 to 30 ng/mL. The Institute of Medicine uses lower cutoffs. Regardless of the threshold, roughly 40% of US adults and 50 to 80% of older adults fall into the deficient or insufficient range at standard cutoffs. ## Mechanism of action Vitamin D3 (cholecalciferol) is biologically inactive until converted to 25-hydroxyvitamin D (calcidiol) in the liver, then to 1,25-dihydroxyvitamin D (calcitriol) in the kidney. Calcitriol acts through the vitamin D receptor (VDR), a nuclear receptor expressed in essentially every tissue, regulating calcium absorption, immune function, cell proliferation, and hundreds of downstream transcriptional targets. The classical bone effects (intestinal calcium absorption, osteoclast/osteoblast regulation) are well-characterized. The non-classical effects (immune modulation, cardiovascular, oncology) are biologically plausible but produce smaller and more variable trial effects than enthusiasts hope. Vitamin K2 menaquinone-7 (MK-7) is a long-chain menaquinone with substantially better tissue distribution and longer plasma half-life (72 hours) than the shorter K2 forms (MK-4 has a 1 to 2 hour half-life, K1 is similarly short). MK-7 carboxylates the glutamic acid residues of vitamin-K-dependent proteins, including osteocalcin (which directs calcium into hydroxyapatite bone matrix), matrix Gla protein (which inhibits vascular calcification), and several coagulation factors. The pharmacological rationale for MK-7 over MK-4 or K1 in supplementation is the longer half-life, which produces more sustained activation of these proteins on once-daily dosing. Absorption of both vitamins is improved with dietary fat. D3 absorption is roughly doubled when taken with a fat-containing meal versus fasted. K2 absorption is more dependent on lipid emulsification and shows substantial inter-individual variation. ## Evidence base by outcome ### Bone health and fracture prevention The largest and most robust outcome. Meta-analyses of vitamin D supplementation at 800 IU/day or above in older adults consistently show 10 to 20% reductions in non-vertebral fractures and similar reductions in falls, particularly when combined with calcium supplementation. The Avenell 2014 Cochrane review and the Bischoff-Ferrari 2012 dose-response analysis are the standard references. K2 supplementation at 45 to 180 mcg/day MK-7 produces small additional improvements in lumbar spine bone mineral density in postmenopausal women across several trials, with the Knapen 2013 trial (n=244, MK-7 180 mcg/day for 3 years) showing measurable BMD preservation versus placebo. ### Mortality and cardiovascular outcomes The VITAL trial (Manson 2019, n=25,871, vitamin D3 2,000 IU/day for 5 years) was largely negative for primary cardiovascular and cancer endpoints. The cardiovascular composite (major adverse events) was unchanged; total cancer incidence was unchanged though cancer mortality showed a non-significant 17% reduction. The pre-specified analysis of fatal cancer plus advanced cancer combined showed a 17% reduction. The interpretation is complicated by 16% of placebo participants taking up to 800 IU/day off-protocol. K2-specific cardiovascular trials are smaller. The Rotterdam study (Geleijnse 2004, n=4,807, observational) reported that high dietary K2 intake was associated with lower coronary artery calcification and reduced cardiovascular mortality. Trial confirmation is limited. ### Immune function Vitamin D supplementation reduces respiratory infection incidence by roughly 10 to 20% in deficient populations, with effect sizes shrinking in replete populations. The Martineau 2017 meta-analysis (25 RCTs, 11,321 participants) supports modest protection against acute respiratory infections, particularly with daily versus bolus dosing. COVID-19 trials in 2020 to 2023 showed mixed results, with some signal for benefit in deficient hospitalized patients and minimal benefit in replete populations. ### Mood and depression Vitamin D and depression have a robust observational association but inconsistent trial effects. The Vellekkatt 2019 meta-analysis (4 RCTs, 948 participants) reported a moderate antidepressant effect (SMD = -0.55) for adults with major depression and low baseline 25(OH)D, but several large primary prevention trials (including VITAL substudy) have been negative in unselected populations. Treat as adjunctive therapy in depression with documented deficiency rather than as broadly indicated. ### Diabetes prevention The D2d trial (Pittas 2019, n=2,423, vitamin D3 4,000 IU/day for 2.5 years in adults with prediabetes) showed a non-significant 12% reduction in progression to T2DM (HR 0.88, p=0.12). Subgroup analyses suggested larger effects in those with lower baseline 25(OH)D. The signal is real but modest. ### Cardiovascular calcification Observational data and small trials suggest that K2 supplementation slows progression of coronary artery calcification in postmenopausal women and patients with kidney disease. The Vossen 2015 trial in CKD patients reported reductions in vascular stiffness markers. Trial evidence is C-tier overall; the mechanistic case for K2 in vascular health is stronger than the trial evidence. ## Dosage and protocols Standard combination dose ranges: - Vitamin D3: 1,000 to 4,000 IU/day for adults (lower end if supplementing without baseline labs, higher end with documented deficiency) - Vitamin K2 MK-7: 90 to 180 mcg/day Dose D3 to target serum 25(OH)D of 30 to 50 ng/mL (75 to 125 nmol/L). The dose-response is roughly 100 IU/day raises 25(OH)D by 1 ng/mL at steady state, with substantial inter-individual variation. Adults with obesity, malabsorption, or limited sun exposure need higher doses. Test 25(OH)D after 8 to 12 weeks of consistent dosing and adjust. MK-7 dose-response is less well-characterized. 180 mcg/day is the dose used in the Knapen bone-health trial; 90 mcg/day is used in many commercial products. The marginal benefit of higher MK-7 doses is modest. Daily dosing outperforms weekly or monthly bolus dosing in immune and infection outcomes. The Lee 2024 meta-analysis specifically found that daily small doses produce more consistent immune effects than periodic large doses. Take with a fat-containing meal. Both vitamins are fat-soluble; absorption is roughly doubled in the fed state. Most commercial combination products use MCT oil or olive oil softgels to improve absorption. No cycling is required. Continuous daily use is the standard approach. Stop high-dose D3 at 8 weeks before any planned hypercalcemia testing. ## Side effects and safety Vitamin D toxicity from supplementation is rare at typical doses. Reports of hypercalcemia and acute kidney injury are concentrated at sustained intakes above 10,000 IU/day or after dosing errors with prescription D2 (which is more potent). Symptoms include fatigue, polyuria, nausea, and altered mental status; serum calcium and 25(OH)D testing confirms. K2 has no documented toxicity at supplemental doses. The K2 form does not interfere with warfarin in the same way that high-dose K1 does, but the effect is not zero, and patients on warfarin should maintain stable K2 intake (rather than starting and stopping high doses) and inform their anticoagulation clinic. Contraindications are narrow. Hypercalcemia, sarcoidosis (granulomatous activation of vitamin D), and active hyperparathyroidism are relative contraindications for vitamin D. Active warfarin therapy is a relative contraindication for K2; consult anticoagulation team. Drug interactions worth noting: thiazide diuretics raise calcium retention and can produce hypercalcemia with high-dose vitamin D. Calcium-channel blockers and digoxin have additive effects with vitamin D-induced hypercalcemia. Glucocorticoids reduce vitamin D efficacy. Pregnancy and lactation use at standard doses (1,000 to 4,000 IU/day D3) is well-tolerated and frequently recommended for fetal bone development. K2 at supplemental doses is not specifically contraindicated but the dedicated pregnancy data are limited. ## Stack interactions and timing The combination naturally pairs with magnesium (magnesium is a cofactor for vitamin D activation; deficiency can blunt D3 supplementation effects), calcium (D3 raises calcium absorption efficiency), and omega-3 (additive cardiovascular benefits). Avoid taking D3/K2 with high-fiber meals or with drugs that bind fat-soluble vitamins (cholestyramine, orlistat). Separate dosing by 2 to 4 hours. Morning dosing is the conventional pattern, but timing within the day is largely irrelevant for chronic supplementation. Some users report sleep disruption with evening D3, with mixed evidence for the effect; daytime dosing avoids the question. ## Practical notes Quality variation is meaningful. Look for products that specify the K2 form as MK-7 (preferred) or MK-4 (shorter half-life, less convenient dosing). Trans-MK-7 is the bioactive isomer; cis-MK-7 is inactive but counted in some assays. Premium products specify trans-MK-7 content or provide third-party testing. Vitamin D3 source can be lanolin (sheep wool, the most common) or lichen-derived (vegan alternative). Both are biologically equivalent. K2 is typically produced by Bacillus subtilis natto fermentation. Cost is moderate. Combination softgels run roughly 10 to 30 cents per dose. Splitting into separate D3 and K2 capsules is cheaper but adds pill burden. Storage is unremarkable. Both vitamins are stable at room temperature in sealed containers for 18 to 24 months. Light exposure degrades vitamin D modestly; opaque or dark glass bottles preserve potency longer. Expect 25(OH)D to plateau at 8 to 12 weeks of consistent dosing. Bone marker effects (CTX, P1NP) appear within 4 to 8 weeks. Bone density effects from K2 take 1 to 3 years to manifest on DEXA. Immune effects on respiratory infection rates are seen across winter seasons, not within weeks.